Author

A. Papadas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. Pagenkopf· 2 shared C. Hope· 2 shared F. Asimakopoulos· 2 shared A. Cicala· 1 shared A. M. Cunningham· 1 shared A. Officer· 1 shared B. Dhakal· 1 shared C. Leith· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Pagenkopf

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment

A. Papadas, G. Deb, A. Officer, A. Cicala, C. Hope, P. Emmerich, J. Wiesner, A. Pagenkopf, G. Arauz, V. Bansal, K. Matkowskyj, D. A. Deming, K. Politi, S. Abrams, O. Harismendy, F. Asimakopoulos

The paper shows that stromal remodeling generates signals that regulate dendritic cell survival and activity, enhancing T-cell inflammation in the tumor microenvironment.

bioRxiv · Nov 10, 2021Immunology

Versican Proteolysis Predicts Immune Effector Infiltration And Post-Transplant Survival In Myeloma

B. Dhakal, A. Pagenkopf, M. U. Mushtaq, A. M. Cunningham, E. Flietner, Z. Morrow, A. Papadas, C. Hope, C. Leith, P. Hematti, P. Hari, N. S. Callander, F. Asimakopoulos

This study shows that VCAN proteolysis predicts CD8+ T cell infiltration and poor survival after myeloma transplantation, suggesting it as a biomarker for relapse risk.

bioRxiv · Sep 12, 2018Immunology